Associated Papers
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Comprehensive Genomic Profiling of Indian Patients With Lung Cancer.
Sharma S et al.
Jco Global Oncology, 2025
Genomics driven precision oncology in advanced biliary tract cancer improves survival.
Kumar-Sinha C et al.
Neoplasia (new York, N.y.), 2023
Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study.
Li HS et al.
Journal of Thoracic Disease, 2022
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.
Attili I et al.
Current Oncology (toronto, Ont.), 2022
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic.
Freitas HC et al.
Frontiers in Oncology, 2020
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A et al.
International Journal of Molecular Sciences, 2019
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.
Wing MR et al.
Oncotarget, 2017
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q et al.
Cancer Chemotherapy and Pharmacology, 2016
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
Tran B et al.
International Journal of Cancer, 2013
Translating genomic research into clinical practice: promise and pitfalls.
Sparano JA et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 2013
Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study.
Doval DC et al.
Journal of Carcinogenesis, 2013
EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
Yam I et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2012
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.
Rajasekaran R et al.
Applied Biochemistry and Biotechnology, 2010
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
Tam IY et al.
Molecular Cancer Therapeutics, 2009
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z et al.
Plos One, 2008
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Tam IY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006